Literature DB >> 24719451

Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels.

Philipp Mertins1, Feng Yang2, Tao Liu2, D R Mani3, Vladislav A Petyuk2, Michael A Gillette3, Karl R Clauser3, Jana W Qiao3, Marina A Gritsenko2, Ronald J Moore2, Douglas A Levine4, Reid Townsend5, Petra Erdmann-Gilmore5, Jacqueline E Snider5, Sherri R Davies5, Kelly V Ruggles6, David Fenyo6, R Thomas Kitchens5, Shunqiang Li5, Narciso Olvera4, Fanny Dao4, Henry Rodriguez7, Daniel W Chan8, Daniel Liebler9, Forest White10, Karin D Rodland2, Gordon B Mills11, Richard D Smith2, Amanda G Paulovich12, Matthew Ellis5, Steven A Carr1.   

Abstract

Protein abundance and phosphorylation convey important information about pathway activity and molecular pathophysiology in diseases including cancer, providing biological insight, informing drug and diagnostic development, and guiding therapeutic intervention. Analyzed tissues are usually collected without tight regulation or documentation of ischemic time. To evaluate the impact of ischemia, we collected human ovarian tumor and breast cancer xenograft tissue without vascular interruption and performed quantitative proteomics and phosphoproteomics after defined ischemic intervals. Although the global expressed proteome and most of the >25,000 quantified phosphosites were unchanged after 60 min, rapid phosphorylation changes were observed in up to 24% of the phosphoproteome, representing activation of critical cancer pathways related to stress response, transcriptional regulation, and cell death. Both pan-tumor and tissue-specific changes were observed. The demonstrated impact of pre-analytical tissue ischemia on tumor biology mandates caution in interpreting stress-pathway activation in such samples and motivates reexamination of collection protocols for phosphoprotein analysis.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24719451      PMCID: PMC4083109          DOI: 10.1074/mcp.M113.036392

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  41 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

2.  Cytoscape: a software environment for integrated models of biomolecular interaction networks.

Authors:  Paul Shannon; Andrew Markiel; Owen Ozier; Nitin S Baliga; Jonathan T Wang; Daniel Ramage; Nada Amin; Benno Schwikowski; Trey Ideker
Journal:  Genome Res       Date:  2003-11       Impact factor: 9.043

3.  iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics.

Authors:  Philipp Mertins; Namrata D Udeshi; Karl R Clauser; D R Mani; Jinal Patel; Shao-en Ong; Jacob D Jaffe; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2011-12-30       Impact factor: 5.911

4.  Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers.

Authors:  Christos Hatzis; Hongxia Sun; Hui Yao; Rebekah E Hubbard; Funda Meric-Bernstam; Gildy V Babiera; Yun Wu; Lajos Pusztai; W Fraser Symmans
Journal:  J Natl Cancer Inst       Date:  2011-10-27       Impact factor: 13.506

5.  Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor.

Authors:  S E Winograd-Katz; A Levitzki
Journal:  Oncogene       Date:  2006-06-19       Impact factor: 9.867

6.  Integrated proteomic analysis of post-translational modifications by serial enrichment.

Authors:  Philipp Mertins; Jana W Qiao; Jinal Patel; Namrata D Udeshi; Karl R Clauser; D R Mani; Michael W Burgess; Michael A Gillette; Jacob D Jaffe; Steven A Carr
Journal:  Nat Methods       Date:  2013-06-09       Impact factor: 28.547

7.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

Authors:  Mona L Gauthier; Hal K Berman; Caroline Miller; Krystyna Kozakeiwicz; Karen Chew; Dan Moore; Joseph Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D Tlsty
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

8.  Whole-genome analysis informs breast cancer response to aromatase inhibition.

Authors:  Matthew J Ellis; Li Ding; Dong Shen; Jingqin Luo; Vera J Suman; John W Wallis; Brian A Van Tine; Jeremy Hoog; Reece J Goiffon; Theodore C Goldstein; Sam Ng; Li Lin; Robert Crowder; Jacqueline Snider; Karla Ballman; Jason Weber; Ken Chen; Daniel C Koboldt; Cyriac Kandoth; William S Schierding; Joshua F McMichael; Christopher A Miller; Charles Lu; Christopher C Harris; Michael D McLellan; Michael C Wendl; Katherine DeSchryver; D Craig Allred; Laura Esserman; Gary Unzeitig; Julie Margenthaler; G V Babiera; P Kelly Marcom; J M Guenther; Marilyn Leitch; Kelly Hunt; John Olson; Yu Tao; Christopher A Maher; Lucinda L Fulton; Robert S Fulton; Michelle Harrison; Ben Oberkfell; Feiyu Du; Ryan Demeter; Tammi L Vickery; Adnan Elhammali; Helen Piwnica-Worms; Sandra McDonald; Mark Watson; David J Dooling; David Ota; Li-Wei Chang; Ron Bose; Timothy J Ley; David Piwnica-Worms; Joshua M Stuart; Richard K Wilson; Elaine R Mardis
Journal:  Nature       Date:  2012-06-10       Impact factor: 49.962

9.  Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.

Authors:  Isabel F Pinhel; Fiona A Macneill; Margaret J Hills; Janine Salter; Simone Detre; Roger A'hern; Ashutosh Nerurkar; Peter Osin; Ian E Smith; Mitch Dowsett
Journal:  Breast Cancer Res       Date:  2010-09-28       Impact factor: 6.466

10.  Mfuzz: a software package for soft clustering of microarray data.

Authors:  Lokesh Kumar; Matthias E Futschik
Journal:  Bioinformation       Date:  2007-05-20
View more
  164 in total

1.  QuantFusion: Novel Unified Methodology for Enhanced Coverage and Precision in Quantifying Global Proteomic Changes in Whole Tissues.

Authors:  Harsha P Gunawardena; Jonathon O'Brien; John A Wrobel; Ling Xie; Sherri R Davies; Shunqiang Li; Matthew J Ellis; Bahjat F Qaqish; Xian Chen
Journal:  Mol Cell Proteomics       Date:  2015-11-23       Impact factor: 5.911

Review 2.  A Biologist's Field Guide to Multiplexed Quantitative Proteomics.

Authors:  Corey E Bakalarski; Donald S Kirkpatrick
Journal:  Mol Cell Proteomics       Date:  2016-02-12       Impact factor: 5.911

3.  Multiplexed, Quantitative Workflow for Sensitive Biomarker Discovery in Plasma Yields Novel Candidates for Early Myocardial Injury.

Authors:  Hasmik Keshishian; Michael W Burgess; Michael A Gillette; Philipp Mertins; Karl R Clauser; D R Mani; Eric W Kuhn; Laurie A Farrell; Robert E Gerszten; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2015-02-27       Impact factor: 5.911

Review 4.  A Fresh Look at the Structure, Regulation, and Functions of Fodrin.

Authors:  Jamuna S Sreeja; Rince John; Dhrishya Dharmapal; Rohith Kumar Nellikka; Suparna Sengupta
Journal:  Mol Cell Biol       Date:  2020-08-14       Impact factor: 4.272

Review 5.  Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer.

Authors:  Yiling Lu; Shiyun Ling; Apurva M Hegde; Lauren A Byers; Kevin Coombes; Gordon B Mills; Rehan Akbani
Journal:  Semin Oncol       Date:  2016-06-15       Impact factor: 4.929

6.  Gld2 activity is regulated by phosphorylation in the N-terminal domain.

Authors:  Christina Z Chung; Nileeka Balasuriya; Emad Manni; Xuguang Liu; Shawn Shun-Cheng Li; Patrick O'Donoghue; Ilka U Heinemann
Journal:  RNA Biol       Date:  2019-05-05       Impact factor: 4.652

7.  Characterization of the Ovarian Tumor Peptidome.

Authors:  Tao Liu; Karin D Rodland; Richard D Smith
Journal:  Vitam Horm       Date:  2018-02-22       Impact factor: 3.421

8.  Attenuation of amyloid-β generation by atypical protein kinase C-mediated phosphorylation of engulfment adaptor PTB domain containing 1 threonine 35.

Authors:  Dennis Dik-Long Chau; Kristen Wing-Yu Yung; William Wai-Lun Chan; Ying An; Yan Hao; Ho-Yin Edwin Chan; Jacky Chi-Ki Ngo; Kwok-Fai Lau
Journal:  FASEB J       Date:  2019-08-05       Impact factor: 5.191

Review 9.  Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.

Authors:  Ralph E Parchment; James H Doroshow
Journal:  Semin Oncol       Date:  2016-07-26       Impact factor: 4.929

10.  Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy.

Authors:  Karsten Krug; Eric J Jaehnig; Shankha Satpathy; Lili Blumenberg; Alla Karpova; Meenakshi Anurag; George Miles; Philipp Mertins; Yifat Geffen; Lauren C Tang; David I Heiman; Song Cao; Yosef E Maruvka; Jonathan T Lei; Chen Huang; Ramani B Kothadia; Antonio Colaprico; Chet Birger; Jarey Wang; Yongchao Dou; Bo Wen; Zhiao Shi; Yuxing Liao; Maciej Wiznerowicz; Matthew A Wyczalkowski; Xi Steven Chen; Jacob J Kennedy; Amanda G Paulovich; Mathangi Thiagarajan; Christopher R Kinsinger; Tara Hiltke; Emily S Boja; Mehdi Mesri; Ana I Robles; Henry Rodriguez; Thomas F Westbrook; Li Ding; Gad Getz; Karl R Clauser; David Fenyö; Kelly V Ruggles; Bing Zhang; D R Mani; Steven A Carr; Matthew J Ellis; Michael A Gillette
Journal:  Cell       Date:  2020-11-18       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.